Following a limited submission
AWMSG advice |
|||
| Status: Recommended with restrictions | |||
Rufinamide (Inovelon®) is recommended as an option for restricted use within NHS Wales. Rufinamide (Inovelon®) is licensed as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients 1 years of age and older. Rufinamide (Inovelon®) is restricted for use where other adjunctive treatments have proved sub-optimal or have not been tolerated. Rufinamide (Inovelon®) is not recommended for use within NHS Wales outside of this subpopulation. |
|||
|
|||
Medicine details |
|||
| Medicine name | rufinamide (Inovelon®) | ||
| Formulation | 40 mg/ml oral suspension | ||
| Reference number | 991 | ||
| Indication | Adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients aged 1 year to < 4 years |
||
| Company | Eisai Ltd | ||
| BNF chapter | Central nervous system | ||
| Submission type | Limited | ||
| Status | Recommended with restrictions | ||
| Advice number | 0919 | ||
| NMG meeting date | 08/05/2019 | ||
| AWMSG meeting date | 19/06/2019 | ||
| Date of issue | 25/06/2019 | ||
| Date of last review | June 2022 | ||
| Further information This advice incorporates and replaces the AWMSG recommendation for rufinamide (Inovelon® ) as an option for use as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients 4 years of age and older where other adjunctive treatments have proved sub-optimal or have not been tolerated (advice number 3312, originally published October 2012). This appraisal recommendation was reviewed in June 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations. |
|||